SRGN and breast cancer: Previous studies have shown that expression of serglycin in the epithelial breast cancer cell line MCF7 (32) and in non-small cell lung cancer cells (NSCLC) (65) evokes their malignant properties, and that chondroitin sulfate chains attached on the serglycin core protein are required for this regulation.